The Impact and Long-Term Potential of Olaratumab in Soft Tissue Sarcoma

2 Ansichten
administrator
administrator
07/18/23

Symantha Melemed, PhD, global product team lead, Oncology Business Unit, Eli Lilly & Company, discusses the impact of the FDA approval of olaratumab (Lartruvo) and its long-term potential in the field of sarcoma.

  • Kategorie

Zeig mehr

0 Bemerkungen Sortiere nach

Keine Kommentare gefunden

Facebook Kommentare

Als nächstes